SARS-CoV-2 Clinical Characteristics and Viral Shedding in Kuwait

Mohammad Alghounaim, Chelsea Caya, Khalid Alothman, Almonther Alhasawi, Jesse Papenburg

Department of Pediatrics, Amiri Hospital, Ministry of Health, Kuwait, Kuwait; McGill University Health Centre Research Institute, Montreal, QC, Canada; Department of Pediatrics, Jaber Alahmad Hospital, Ministry of Health, Kuwait, Kuwait; Department of Medicine, Infectious Diseases Hospital, Ministry of Health, Kuwait, Kuwait; Division of Pediatric Infectious Diseases, The Montreal Children’s Hospital, McGill University Health Centre, Montreal, QC, Canada; Division of Microbiology, Department of Laboratory Medicine, McGill University Health Centre, Montreal, QC, Canada

Abstract

Objectives: We aimed to describe the clinical characteristics of SARS-CoV-2 infection and estimate viral shedding duration in respiratory specimens. Methods: A retrospective cohort study was performed from February 25 to March 25, 2020. In Kuwait, all suspected coronavirus disease 2019 (COVID-19) cases, contacts of cases, and returning travelers were systematically tested for SARS-CoV-2 by RT-PCR. All infected persons, regardless of symptoms, were hospitalized and serially tested until they had two negative results. Descriptive statistics and regression analyses were performed. Results: Two hundred seven cases of SARS-CoV-2 infection were included in this study. About half of the cases were asymptomatic and 1.9% died. The median time to negative RT-PCR was 22 days. Increasing age, ARDS, and low peripheral white blood cell count were associated with prolonged PCR positivity. Conclusion: Predictors for prolonged RT-PCR positivity included increasing age, ARDS, and low white blood cell count. The findings of this study may aid in better understanding of the epidemiology of SARS-CoV-2 infection and molecular testing dynamics.
Introduction

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus and the causative agent of coronavirus disease 2019 (COVID-19). Disease severity ranges from asymptomatic infection to acute respiratory distress syndrome (ARDS) and respiratory failure; however, the exact proportion of each clinical category is not fully known [1]. For instance, the reported prevalence of asymptomatic persons among SARS-CoV-2 infections has ranged from 6.3 to 96.0% [2–4].

To limit community transmission, several countries, including Kuwait, adopted isolation measures for all cases of SARS-CoV-2 infection until they are no longer considered infectious as demonstrated by 2 consecutive negative real-time polymerase chain reaction (RT-PCR) results from respiratory specimens [5, 6]. We aimed to estimate the duration of SARS-CoV-2 shedding among infected patients in Kuwait using RT-PCR from paired nasopharyngeal and oropharyngeal specimens. Our secondary objective was to describe the clinical characteristics among SARS-CoV-2 infections.

Methods

We performed a national, single-center retrospective cohort study at Jaber Alahmad Hospital (JAH) of the Ministry of Health, Kuwait. Patients admitted from February 25 to March 25, 2020, with SARS-CoV-2 infection were followed until discharge. During the study period, by ministerial decree, all persons with COVID-19 symptoms, returning travelers, and close contacts of SARS-CoV-2 cases were tested for SARS-CoV-2 by RT-PCR. All confirmed cases were admitted to JAH regardless of their symptoms until they had 2 consecutive negative RT-PCR results. On April 15, 2020, patient discharge policy was changed due to limits in bed capacity, and patients were given the option to be discharged to institutional quarantine. Patient charts were reviewed to obtain relevant clinical and laboratory data. Disease severity categorization was based on the WHO classification [1].

Paired nasopharyngeal and oropharyngeal swabs were collected routinely as per the discretion of the treating team, typically every 3–5 days throughout the admission. Nucleic acid extraction and RT-PCR were performed on MagNA Pure and Light Cycler 480 (RocheTM, Basel, Switzerland). RT-PCR cycle threshold (Ct) value for the E and RdRP gene targets was measured using Tib MolBiol’s LightMix (RocheTM, Basel, Switzerland).

Descriptive statistics were performed. Patients with severe COVID-19 as per WHO classification (severe pneumonia, ARDS, and sepsis/septic shock) were compared to those with asymptomatic or mild infection using χ²/Fisher’s exact test or Wilcoxon test as appropriate. Predictors for duration of RT-PCR positivity were estimated using negative binomial regression. Multiple imputation using the MICE package in R was performed to estimate missing values for time to negativity.

Results

During the study period, we identified 207 SARS-CoV-2 hospitalizations in Kuwait. Median age of patients was 48.9 (IQR 28.9–60.5) and 48.8% were males (Table 1). Approximately half of the patients (51.7%, 95% CI: 44.9–58.4; 46.7% of these patients were male) did not develop COVID-19 symptoms prior to, or during, their hospitalization. When compared with asymptomatic or mild infections, patients with severe disease had longer median hospital LOS (37 vs. 25 days; p < 0.001) and were more likely to have comorbid conditions (83.3% vs. 47.6%; p = 0.008) and to be prescribed antibiotics (100.0% vs. 16.4%; p < 0.001). One patient with mild COVID-19 was admitted to the ICU for reasons not related to the infection and did not require respiratory support. Four patients died (1.9%, 95% CI: 0.75–4.8).

On admission, patients with severe disease had lower median lymphocyte count (1.20 vs. 1.85; p < 0.001) and higher C-reactive protein (33.0 vs. 5.0; p < 0.001) and procalcitonin (0.115 vs. 0.046; p < 0.001) levels. Co-infections were uncommon. Four patients had documented bacterial or fungal infection (3 bacteremia, 1 candidemia, 2 urinary tract infection, and 2 ventilator-associated pneumonia).

Time to 2 negative consecutive RT-PCR results was 22 days (IQR 14.75–27) among asymptptomatically infected subjects. Viral shedding was significantly longer in severe disease (31 days [IQR 26–36.5]) compared to mild disease/asymptomatic infection (22 days [IQR 15–27.5]; p = 0.001). Increasing age, ARDS, and low peripheral WBC count were significant predictors for longer time to negative RT-PCR in multivariable analysis (Table 2).

Of the study population, 53 subjects were discharged earlier to an institutional quarantine and, hence, did not fulfill the criteria for 2 consecutive negative RT-PCR, and missing values were imputed. Also, imputation of missing values of CRP (n = 5), PCT (n = 15), and date of discharge (n = 1) was performed.

Discussion

In this national study of SARS-CoV-2 infections, we observed prolonged RT-PCR positivity with median duration ranging from 19.5 to 40 days across disease severity categories. Older age, ARDS, and low WBC were significantly associated with prolonged PCR positivity in a multivariable model.
Table 1. Patient demographics, clinical data, and laboratory investigations

| Variables                      | Asymptomatic (N = 107), n (%) | Mild illness (N = 67), n (%) | Mild pneumonia (N = 15), n (%) | Severe pneumonia (N = 7), n (%) | ARDS (N = 8), n (%) | Sepsis/septic shock (N = 3), n (%) |
|--------------------------------|-------------------------------|-----------------------------|-------------------------------|-------------------------------|-------------------|-----------------------------------|
| Age (median, IQR), years       | 41.2 (27.9–59.5)             | 41.8 (28.1–54.0)            | 56.1 (51.0–65.3)              | 68.0 (64.9–71.7)             | 60.9 (53.2–64.6)  | 72.9 (68.5–75.4)                  |
| Gender (male)                  | 50 (46.7)                    | 36 (53.7)                   | 6 (40.0)                      | 3 (42.9)                      | 5 (62.5)          | 1 (33.3)                          |
| Children, <18 years            | 8 (7.5)                      | 0                           | 0                             | 0                             | 0                 | 0                                 |
| Comorbid conditions            |                               |                             |                               |                               |                   |                                   |
| None                           | 59 (55.1)                    | 35 (52.2)                   | 5 (33.3)                      | 1 (14.3)                      | 2 (25.0)          | 0                                 |
| Autoimmune                     | 0                            | 2 (3.0)                     | 0                             | 0                             | 0                 | 0                                 |
| Bronchial asthma               | 8 (7.5)                      | 3 (4.5)                     | 4 (26.7)                      | 1 (14.3)                      | 1 (12.5)          | 0                                 |
| Cardiac                        | 7 (6.5)                      | 4 (6.0)                     | 3 (20.0)                      | 0                             | 3 (37.5)          | 2 (66.7)                          |
| Diabetes mellitus              | 23 (21.5)                    | 7 (10.4)                    | 6 (40.0)                      | 3 (42.9)                      | 4 (50.0)          | 2 (66.7)                          |
| Hypertension                   | 25 (23.4)                    | 16 (23.9)                   | 5 (33.3)                      | 5 (71.4)                      | 5 (62.5)          | 3 (100)                           |
| Malignancy                     | 3 (2.8)                      | 1 (1.5)                     | 2 (13.3)                      | 0                             | 0                 | 0                                 |
| Others*                        | 4 (3.7)                      | 4 (6.0)                     | 0                             | 0                             | 2 (25.0)          | 1 (33.3)                          |
| Symptoms                       |                               |                             |                               |                               |                   |                                   |
| Fever                          | 0                            | 26 (38.8)                   | 7 (46.7)                      | 5 (71.4)                      | 5 (62.5)          | 3 (100)                           |
| Duration of fever (median, IQR), days | NA                       | 3 (2–6)                     | 4 (2.5–4.75)                  | 6 (2–7)                       | 5 (2–5)           | 2 (1.5–3)                         |
| Cough                          | 0                            | 46 (68.7)                   | 8 (53.3)                      | 5 (71.4)                      | 5 (62.5)          | 3 (100)                           |
| Runny nose                     | 0                            | 18 (26.9)                   | 2 (13.3)                      | 0                             | 0                 | 0                                 |
| Gastrointestinal symptoms      | 0                            | 21 (31.3)                   | 1 (6.7)                       | 1 (14.3)                      | 0                 | 0                                 |
| Shortness of breath            | 0                            | 1 (1.5)                     | 1 (6.7)                       | 4 (57.1)                      | 6 (75.0)          | 1 (33.3)                          |
| Myalgia/headache               | 0                            | 24 (35.8)                   | 5 (33.3)                      | 5 (71.4)                      | 4 (50.0)          | 1 (33.3)                          |
| Hospital LOS (median, IQR), days | 25 (19–30)                 | 25 (23–29.5)                | 24 (19–31)                    | 36 (32–39.5)                  | 35.5 (32.75–47.5) | 53 (46–60)                        |
| ICU admission                  | 0                            | 1 (1.5)                     | 0                             | 2 (28.6)                      | 8 (100)           | 3 (100)                           |
| ICU LOS (median, IQR), days    | NA                           | 3 (3–3)                     | NA                            | 3 (2.5–3.5)                   | 21 (10.75–35)     | 59 (34.5–67)                      |
| Highest level of respiratory support |                       |                             |                               |                               |                   |                                   |
| None                           | 107 (100)                    | 67 (100)                    | 15 (100)                      | 1 (14.3)                      | 0                 | 0                                 |
| Oxygen                         | 0                            | 0                           | 0                             | 6 (85.7)                      | 0                 | 0                                 |
| Invasive ventilation           | 0                            | 0                           | 0                             | 6 (75.0)                      | 2 (66.7)          |                                   |
| ECMO                           | 0                            | 0                           | 0                             | 0                             | 2 (25.0)          | 1 (33.3)                          |
| Laboratory values on admission |                               |                             |                               |                               |                   |                                   |
| WBC (median, IQR)              | 5.3 (4.1–6.4)                | 5.2 (4.1–6.6)               | 4.9 (4.0–5.7)                 | 4.1 (3.4–4.4)                | 3.9 (3.6–6.2)     | 4.4 (3.6–4.9)                     |
| ANC (median, IQR)              | 2.5 (2.0–3.6)                | 2.8 (2.0–3.9)               | 2.7 (1.6–3.3)                 | 2.4 (1.8–2.7)                | 2.6 (2.0–4.4)     | 2.1 (2.1–3.0)                     |
| ALC (median, IQR)              | 2.0 (1.4–2.6)                | 1.6 (1.2–2.1)               | 1.4 (0.9–2.1)                 | 1.3 (1.2–1.5)                | 0.9 (0.6–1.3)     | 1.0 (0.7–1.3)                     |
| CRP (median, IQR)              | 4.0 (2.2–7.7)                | 7.0 (3.5–13.5)              | 16.0 (7.0–52.5)               | 33.0 (22.0–91.5)             | 26.5 (15.0–102.5) | 81.0 (43.5–132.5)                 |
| Chest X-ray findings           |                               |                             |                               |                               |                   |                                   |
| Normal or increased bronchovascular marking | 99 (92.5)              | 60 (89.5)                   | 0                             | 0                             | 0                 | 0                                 |
| Bilateral ground-glass opacity | 5 (4.7)                      | 5 (7.4)                     | 12 (80)                       | 7 (100)                      | 8 (100)           | 3 (100)                           |
| Consolidation                  | 1 (0.9)                      | 0                           | 3 (20)                        | 0                             | 0                 | 0                                 |
| Chest CT performed             | 0                            | 0                           | 0                             | 2 (28.6)                      | 4 (50.0)          | 3 (100)                           |
| Days to second consecutive negative RT-PCR (median, IQR) | 22 (14.75–27)            | 23 (19.5–28)                | 19.5 (15–27.25)               | 33 (26–35)                   | 40 (30–54.5)      | 25.5 (25.25–25.75)                |

ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CRP, C-reactive protein; CT, computer tomography; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; LOS, length of stay; PCT, procalcitonin; RT-PCR, reverse transcriptase polymerase chain reaction; WBC, white blood cell. * Other comorbidities include chronic kidney disease (n = 2), chronic hepatitis B virus infection (n = 2), nephrectomy (n = 1), obesity (n = 2), obstructive sleep apnea (n = 1), pregnant (n = 2), and trisomy 21 (n = 1).
Other studies have reported similar durations of viral shedding. Among 137 COVID-19 survivors from Wuhan, median time of RT-PCR positivity was 20.0 days (IQR 17.0–24.0) [7]. In another study, median viral shedding was 31.0 days (IQR 24.0–40.0) without difference in gender or age [8]. Estimation of viral shedding based on RT-PCR positivity was the standard of care at the beginning of the pandemic [5]. However, detectable SARS-CoV-2 RNA may not represent viable virus. Recent evidence suggests that SARS-CoV-2 is not isolated from cell culture after 8–10 days of illness onset [9–11]. However, viral detection in cell culture is less sensitive than RT-PCR, and cycle threshold value correlates with cultivatable virus [12, 13]. Hence, further studies examining the duration of viral shedding are needed to better determine the contagious period.

We found that more than half of the SARS-CoV-2 infections were asymptomatic. This may be an accurate reflection of the asymptomatic SARS-CoV-2 infection rate as, during the study period, public health policy dictated that RT-PCR testing be systematically done on all returning travelers and close contacts at least twice: at arrival and after 14 days. Also, asymptomatic patients were all admitted and observed daily for the development of symptoms. Our longitudinal study was thus able to distinguish asymptomatic cases from pre-symptomatic individuals that eventually develop symptoms. Our asymptomatic proportion is much higher than modeling estimates based on European data (17.9%; 95% CI: 15.5–20.2%). However, our findings are in line with a recent review that found that approximately 40%–50% of those infected with SARS-CoV-2 will remain asymptomatic, and that they can transmit the virus for perhaps longer than 14 days [3, 4].

Our study was limited by the small number of patients with critical illness. This affected our ability to precisely evaluate the association between duration of viral shedding and disease severity. Also, the majority of patients had RT-PCR performed in a different laboratory prior to admission and some after discharge to quarantine. The Ct values and results of these tests were not accessible to the authors. Nevertheless, our longitudinal design and systematic screening of all returning travelers and COVID-19 case contacts in Kuwait gives a more accurate estimate of asymptomatic infections.

**Conclusion**

Asymptomatic SARS-CoV-2 is common, and the duration of RT-PCR positivity varies according to disease severity, age, and white blood cell counts. The findings of this study shed light on the understanding of the dynamics of results of SARS-CoV-2 molecular testing. Further studies are needed to evaluate the impact of prolonged RT-PCR positivity on public health measures.

### Table 2. Negative binomial regression analyses to identify predictors for time to RT-PCR negativity

| Covariate                        | Univariable model | Multivariable model |
|----------------------------------|-------------------|---------------------|
|                                  | coefficient       | 95% CI              | coefficient       | 95% CI              |
| Age                              | 1.004             | 1.001–1.007         | 1.004             | 1.000–1.008         |
| Male gender                      | 0.983             | 0.878–1.099         | N/A               |                     |
| Disease severity                 |                   |                     |                   |                     |
| Asymptomatic                     | N/A               |                     | Reference         |                     |
| Mild illness                     | 1.062             | 0.939–1.201         | 1.124             | 0.986–1.283         |
| Mild pneumonia                   | 0.934             | 0.751–1.169         | 0.924             | 0.738–1.161         |
| Severe pneumonia                 | 1.417             | 1.059–1.924         | 1.196             | 0.870–1.662         |
| ARDS                             | 1.223             | 0.926–1.636         | 1.792             | 1.287–2.542         |
| Sepsis/septic shock              | 0.887             | 0.559–1.446         | 1.069             | 0.654–1.801         |
| Peripheral blood laboratory values on admission |                   |                     |                   |                     |
| C-reactive protein               | 0.999             | 0.998–1.001         | N/A               |                     |
| Procalciton                      | 0.555             | 0.333–0.935         | N/A               |                     |
| White blood cell count           | 0.948             | 0.928–0.969         | 0.957             | 0.934–0.980         |
| Absolute neutrophil count        | 0.925             | 0.895–0.957         | N/A               |                     |
| Absolute lymphocyte count        | 0.964             | 0.933–0.997         | N/A               |                     |
Statement of Ethics

This study was approved by the Ethics Board of the Ministry of Health (2020/1408).

Conflict of Interest Statement

J.P. has received consulting/honoraria fees from AbbVie, Cepheid, and Seegene and research grant funding outside of the current study from AbbVie, BD Diagnostics, Sanofi Pasteur, and MedImmune.

Funding Sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1 World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected: interim guidance V1.2; 2020. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
2 Mizumoto K, Kagaya K, Zarebski A, Chowel G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020: 25.
3 Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020 May;94:154.
4 Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 Infection: a narrative review. Ann Intern Med. 2020;M20–3012.
5 Wong JEL, Leo YS, Tan CC. COVID-19 in Singapore-current experience: critical global issues that require attention and action. JAMA. 2020;323(13):1243.
6 Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. J Clin Virol. 2020; 127:104346.
7 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
8 Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis. 2020; 71(16):2240.
9 La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldi C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059–61.
10 Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;101738.
11 Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis. 2020;71(10):2663.
12 AlGhounaim M, Xiyo Y, Caya C, Papenburg B. Diagnostic yield and clinical impact of routine cell culture for respiratory viruses among children with a negative multiplex RT-PCR result. J Clin Virol. 2017;94:107–9.
13 Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25(32):2001483.